Enhancing bacteriophage therapeutics through in situ production and release of heterologous antimicrobial effectors.

Bibliographic Details
Title: Enhancing bacteriophage therapeutics through in situ production and release of heterologous antimicrobial effectors.
Authors: Du, Jiemin, Meile, Susanne, Baggenstos, Jasmin, Jäggi, Tobias, Piffaretti, Pietro, Hunold, Laura, Matter, Cassandra I., Leitner, Lorenz, Kessler, Thomas M., Loessner, Martin J., Kilcher, Samuel, Dunne, Matthew
Source: Nature Communications; 7/20/2023, Issue 1, p1-10, 10p
Subject Terms: BACTERIOPHAGES, ESCHERICHIA coli, URINARY tract infections, COMPANION diagnostics, DRUG resistance in bacteria, ENGINEERS
Abstract: Bacteriophages operate via pathogen-specific mechanisms of action distinct from conventional, broad-spectrum antibiotics and are emerging as promising alternative antimicrobials. However, phage-mediated killing is often limited by bacterial resistance development. Here, we engineer phages for target-specific effector gene delivery and host-dependent production of colicin-like bacteriocins and cell wall hydrolases. Using urinary tract infection (UTI) as a model, we show how heterologous effector phage therapeutics (HEPTs) suppress resistance and improve uropathogen killing by dual phage- and effector-mediated targeting. Moreover, we designed HEPTs to control polymicrobial uropathogen communities through production of effectors with cross-genus activity. Using phage-based companion diagnostics, we identified potential HEPT responder patients and treated their urine ex vivo. Compared to wildtype phage, a colicin E7-producing HEPT demonstrated superior control of patient E. coli bacteriuria. Arming phages with heterologous effectors paves the way for successful UTI treatment and represents a versatile tool to enhance and adapt phage-based precision antimicrobials. Du et al. genetically engineer bacteriophages into heterologous effector phage therapeutics, enabling dual phage- and effector-mediated targeting for a two-pronged attack against bacterial pathogens. [ABSTRACT FROM AUTHOR]
Copyright of Nature Communications is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Complementary Index
More Details
ISSN:20411723
DOI:10.1038/s41467-023-39612-0
Published in:Nature Communications
Language:English